OOIR: Observatory of International Research

Papers

(The median citation count of JACC: Cardiooncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Editorial Board	127
Full Issue PDF	120
Full Issue PDF	110
Atrial Fibrillation in Patients With Cancer	110
Full Issue PDF	100
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	91
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	88
Priorities in Cardio-Oncology	87
Epigenomics of Cardio-Oncology	87
Hormonal Therapy and Cardiovascular Health	81
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	63
Cardiovascular Safety in Oncology Clinical Trials	63
Cardiac Magnetic Resonance in Cardio-Oncology	56
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	56
Balancing Promise and Evidence	51
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	51
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	48
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	48
Full Issue PDF	47
Full Issue PDF	47
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	45
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	45
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	44
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	43
Cardiac Risk Stratification Before Lung Cancer Radiation	42

Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	41
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	41
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	40
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	38
Frailty	38
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	36
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	33
Permissive Cardiotoxicity	33
Cancer Immunotherapy Beyond Checkpoint Blockade	33
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	32
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	32
The Need for an Early Biomarker of Cardiovascular Disease in Survivors of Hodgkin Lymphoma	31
Editorial Board/Officers Page	30
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	30
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	29
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	29
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	28
Endothelin-1	27
Leveling Up	27
Editorial Board	26
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	25
Full Issue PDF	25
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	25
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	24
Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States	23
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	23
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	23
Developing a Model for Cross-Institutional Educational Collaborations	22
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	22
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	21
Quality-of-Care Measures for Cardio-Oncology	21
JACC: CardioOncology	20
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	20
Vascular Complications of Atrial Fibrillation in Patients With Cancer	20
The United Kingdom’s First Cardio-Oncology Service	18
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	18
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	18
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	18
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy	17
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	16
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer	16
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	16
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	15
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	15
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	15
Fluoropyrimidine Therapy in Gastrointestinal Cancer	15
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	15
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	14
Post-Transplantation Cyclophosphamide	14
Low QRS Voltages in Cardiac Amyloidosis	14

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	14
CHA2DS2-VASc Score in Cardio-Oncology	14
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	14
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	13
How to Perform Hematopoietic Stem Cell Transplantation	13
Hearts on the Minds of Oncologists	13
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	13
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	13
Cancer and Clot	13
To Adjudicate or Not Adjudicate	13
Full Issue PDF	13
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	13
Editorial Board	13
Author Index	12
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	12
ABSTRACT WITHDRAWN	12
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	12
Donor-Derived Testicular Germ Cell Cancer in a Heart Transplant Recipient	12
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	12
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	11
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	11
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	11
Cancer Therapy–Related Cardiac Dysfunction	11
Cardiovascular Considerations After Cancer Therapy	11
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	11
JACC: CardioOncology	10
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	10
(Less) Time and Energy	10
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	10
Clinical Practice Guidelines in Cardio-Oncology	10
Guiding Treatment With Recovered CTRCD	10
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	10
Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies	10
Addressing the Overlooked	9
Navigating the Uncharted	9
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	9
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	9
Reply	9
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy	9
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	9
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	9
The Cause of Death in Patients With Cancer	9
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	9
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	9
Preventing Cancer Therapy–Related Cardiotoxicity	8
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	8
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	8
Editorial Board/Officers Page	8
Reply	8
Full Issue PDF	8
Learning From Trials	8
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	8
Reply	8
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	8
Reply	8
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	8
Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma	7
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	7
The ESC Cardio-Oncology Guidelines	7
Reply	7
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	7
Reply	7
Overcoming LGBTQI+ Disparities in Cardio-Oncology	7
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	7
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	7
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	7
Full Issue PDF	7
Amyloid Cardiomyopathy	7
When Clot Is Tumor	7
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	7
Assessing STEMI Outcomes in Patients With Cancer	7
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	7
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer	6
Editorial Board	6
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	6
Physical Inactivity, Adverse Body Composition, and Cardiac Function in Breast Cancer Survivors	6
Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome	6
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors	6
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	6

Cancer Diagnosis, Physical Activity, and Heart Disease Risk	6
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy	6
Melanoma Treatment	6
Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy	6
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma	6
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	6
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	6
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION	6
Leukemia and Heart Disease	6
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes	6
Pumping Up the Standards	5
Editorial Board	5
MARANTIC ENDOCARDITIS - DIAGNOSTIC AND MANAGEMENT CHALLENGES	5
Reduced Thoracic Aortic Distensibility Upon Breast Cancer Diagnosis (WF-97415 and WF-98213)	5
AL Amyloidosis for Cardiologists	5
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey	5
Incident Cancer in Heart Failure Patients and the Need for Additional Investigations	5
Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis	5
Full Issue PDF	5
New Cardiotoxicity Risk Assessment Guidelines	5
Risk of Incident Heart Failure Among Young Adult Cancer Survivors	5
Mediterranean Diet Is Associated With Lower All-Cause and Cardiovascular Mortality Among Long-Term Cancer Survivors	5
Racial and Ethnic Disparities in Cardio-Oncology	5
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis	5
Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients	5
Ablating Late Cardiovascular Events in Modern Hematopoietic Cell Transplantation	5
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer	5
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors	5
More Data to Support a Cardiac-Oncologic Partnership	4
Editorial Board	4
Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib	4
Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis	4
Determinants of Impaired Peak Oxygen Uptake in Breast Cancer Survivors: JACC: CardioOncology Primer	4
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification	4
Potential and Pitfalls of Pharmacovigilance Databases in Oncology	4
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis	4
Cancer-Associated Venous Thromboembolism	4
Two Decades of Cardiac Amyloidosis	4
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT	4
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer	4
Significance of Alectinib-Induced Bradycardia	4
Predictors of Atrial Fibrillation After Thoracic Radiotherapy	4
Reply	4
Reply	4
Raise the Flag	3
Full Issue PDF	3
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	3
Reply	3
Embracing the Power of the Polysocial Risk Score	3
Management of Amyloid Cardiomyopathy in Resource-Constrained Settings	3
Full Issue PDF	3
Articulating the JACC Journals’ Direction in Times of Global Change	3
Steroids in Immune Checkpoint Inhibitor Myocarditis	3
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies	3
Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without Cancer	3
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities	3
Transcatheter Compared With Surgical Aortic Valve Replacement in Patients With Previous Chest-Directed Radiation Therapy	3
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer	3
Is Preventative Oophorectomy Safe?	3
Probing the Anthracycline-Induced Myocardial Injury	3
Editorial Board/ACC Officers Page	3
Cardio-Oncology and Health Equity	3
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome	3
How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis	3
Cardiovascular Disease in Myeloproliferative Neoplasms	3
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults	3
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity	3
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors	3
Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies	3
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	3
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan	3
Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance	3
Editorial Board/Officers Page	3
Editorial Board	3
Driven by Impact, Not Impact Factor	3
Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors	3
SARCOIDOSIS MIMICKING CARDIAC AMYLOIDOSIS: A CHALLENGING CONUNDRUM	3
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy	3
How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk	3
Reply	2
Clonal Hematopoiesis Is Associated With Cardiomyopathy During Solid Tumor Therapy	2
Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer	2
A Picture Is Worth 2,000 Words	2
How to Manage Cisplatin-Based Chemotherapy–Related Cardiovascular Disease in Patients With Testicular Cancer	2
RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy	2
Cardio-Oncology Guidelines and Strength of the Evidence	2
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues	2
Cardio-Oncology in Chile	2
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer	2
Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort	2
Sustained Increases in IGFBP-7 May Be Related to Doxorubicin in Breast Cancer Patients	2
Diversity in Cardio-Oncology Clinical Trials	2
Light-Chain Pericardial Amyloidosis Emerging Alongside Variant Transthyretin Cardiac Amyloidosis	2
How to Apply Translational Models to Probe Mechanisms of Cardiotoxicity	2
Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer	2